Patient Access and Support

It is our goal to provide you with the support and tools to help appropriate patients receive SIGNIFOR^® LAR

All prescriptions will be filled through our specialty pharmacy network

Reimbursement support for your office

Benefits verification
Prior authorization/appeals support
Copay Assistance Program*
Assists patients ineligible for copay assistance in identifying charitable foundations

Clinician case managers and nurse support

Medical professionals are available to help support your patients

Financial assistance during insurance gaps

Helps patients start or remain on therapy in the event an access or insurance gap arises

Patient Assistance Program (PAP) for indigent patients

*Eligibility requirements, restrictions, and limitations apply.

Contact the R.A.R.E. Patient Support Program for Assistance

Monday-Friday between 9:00 _AM and 6:00 _PM ET:

Phone: 1-888-855-RARE (7273) Fax: 1-855-813-2039

GET YOUR PATIENTS STARTED WITH SIGNIFOR LAR

FIND RESOURCES FOR YOUR PATIENTS

Indications and Usage

SIGNIFOR LAR (pasireotide) is a somatostatin analog indicated for the treatment of:

Patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option

Patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative

Important Safety Information

Warnings and Precautions

Hyperglycemia, Diabetes, and Ketoacidosis: SIGNIFOR LAR can cause increases in blood glucose levels which are sometimes severe. Monitor glucose levels as clinically appropriate during therapy. There have been postmarketing cases of ketoacidosis with SIGNIFOR LAR in patients with history of diabetes and in patients without history of diabetes. Patients who develop significant hyperglycemia on SIGNIFOR LAR may require initiation of anti-diabetic treatment or adjustment in their current anti-diabetic treatment. The optimal treatment for the management of SIGNIFOR LAR-induced hyperglycemia is not known. If hyperglycemia cannot be controlled despite medical management, reduce the dose or discontinue SIGNIFOR LAR. If ketoacidosis is suspected, discontinue SIGNIFOR LAR and promptly evaluate and treat the patient. Please see sections 2.1, 5.1 in full Prescribing Information.

Indications and Usage

SIGNIFOR LAR (pasireotide) is a somatostatin analog indicated for the treatment of:

Patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option

Patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative

Important Safety Information

Warnings and Precautions

Bradycardia and QT Prolongation: Bradycardia has been reported with the use of SIGNIFOR LAR (pasireotide). Patients with cardiac disease and/or risk factors for bradycardia, such as history of clinically significant bradycardia, high grade heart block, or concomitant use of drugs associated with bradycardia, should be monitored. Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR (pasireotide) treatment. Use with caution in at-risk patients; evaluate ECG and electrolytes prior to dosing and periodically while on treatment

Liver Test Elevations: Evaluate liver enzyme tests prior to and during treatment. Please see sections 2.1, 5.3 in full Prescribing Information

Cholelithiasis and Complications of Cholelithiasis: Monitor periodically. Discontinue if complications of cholelithiasis are suspected. Please see section 5.4 in full Prescribing Information

Pituitary Hormone Deficiency(ies): Monitor for occurrence periodically and treat if clinically indicated. Please see section 5.5 in full Prescribing Information

Adverse Reactions

Adverse drug reactions associated with SIGNIFOR LAR (pasireotide) and occurring in ≥20% of patients were diarrhea, cholelithiasis, hyperglycemia and diabetes mellitus

To report SUSPECTED ADVERSE REACTIONS, contact Recordati Rare Diseases Inc. at 1-888-575- 8344, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

Drug Interactions

Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation

Cyclosporine: Consider additional monitoring

Bromocriptine: Consider bromocriptine dose reduction

Females and Males of Reproductive Potential

Advise premenopausal females of the potential for an unintended pregnancy

Signifor

Consider the source

Recordati Rare Diseases created the R.A.R.E.™ Patient Support Program to help you and your patients every step of the way.

It is our goal to provide you with the support and tools to help appropriate patients receive SIGNIFOR^® LAR

All prescriptions will be filled through our specialty pharmacy network

Contact the R.A.R.E. Patient Support Program for Assistance

Indications and Usage

Important Safety Information

Warnings and Precautions

Indications and Usage

Important Safety Information

Warnings and Precautions

Adverse Reactions

Drug Interactions

Females and Males of Reproductive Potential

Consider the source